Drug intelligence / Profile preview

Yijing Buqi Yangxue Prescription

Development stage: Preclinical
Administration: Oral

Overview

Yijing Buqi Yangxue Prescription (YBYP) is a Traditional Chinese Medicine (TCM) compound prescription composed of several Chinese herbs, including Semen Cuscutae (Tusizi), Angelica Sinensis (Danggui), and Glycyrrhiza Uralensis Fisch (Gancao). It is being investigated for its potential as an antineoplastic agent, primarily by inhibiting the proliferation of esophageal cancer cells through the activation of T cells and the regulation of various intracellular signaling pathways.

Beyond the preview

Go deeper on Yijing Buqi Yangxue Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yijing Buqi Yangxue Prescription.

Explore the full profile